Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

September 8, 2017: By Jon Swedien
Ellex iTrack microcatheter

Ellex iTrack microcatheter

Ellex Medical Lasers Limited will increase the production of its iTrack canaloplasty microcatheter from 20 thousand annually to 50 thousand, the Australian company announced Sept. 4.

The company is expanding and upgrading its manufacturing facility in Fremont, California. Ellex plans to complete the expansion by July 2018.

In July, Ellex increased production capacity at the Fremont site to 20 thousand units per year from 10 thousand, the company said.

Ellex said it sold about 10 thousand iTrack devices in its 2017 fiscal year that ended June 30.

Meanwhile, Ellex said it has already begun planning for a third production increase that would enable the plant to produce upward of 100 thousand units per year.

In December 2016, the company sold shares to raise $10.3 million to support sales of the iTrack in the US and China.

The Centers for Medicare and Medicaid Services in November 2016 increased the reimbursement available to ASCs purchasing and using the iTrack to $1,747 per procedure in 2017, up from $976 in 2016.

In canaloplasty, the iTrack is inserted into Schlemm’s canal, where it can open or dilate the full 360 degrees of Schlemm’s canal.

Ellex acquired the iTrack in 2014.

Headquartered in Adelaide, Australia, Ellex offers ophthalmic lasers and devices to treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, and age-related macular degeneration.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023